We initially confirmed the downregulation of pulmonary SMAD3 phosphorylation, a proxy for TGFβ1R target engagement, following ALK5i treatment in BLEO‐IPF mice. This evidence concerns the gene SMAD3 and idiopathic pulmonary fibrosis.